SOHO21

Bijal Shah, MD, MSAcute Lymphoblastic Leukemia | February 2, 2023
At SOHO 2021, Bijal Shah, MD, MS, of Moffitt Cancer Center, discussed what to expect going forward.
Greg Nowakowski, MDAggressive B-Cell Lymphoma | November 14, 2022
At SOHO 2021, Greg Nowakowski, MD, of Mayo Clinic Rochester, discusses what to expect.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | November 15, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Advertisement
Brandon MayMyeloproliferative Neoplasms | May 30, 2023
REVEAL is the largest prospective and contemporary cohort of patients with PV in the United States.
Brandon MayChronic Myeloid Leukemia | September 30, 2024
The OPTIC study evaluated a response-based dose-reduction strategy to optimize the benefit-risk of a TKI in CP-CML.
Brandon MayChronic Lymphocytic Leukemia | February 2, 2023
In patients with previously treated CLL and SLL, pirtobrutinib was safe and associated with high rates of response.
Advertisement
Farhad Ravandi, MDAcute Myeloid Leukemia | May 22, 2023
Farhad Ravandi, MD, and Jeffrey Lancet, MD, squared off on this clinical quandary.
Advertisement
Advertisement